Catalent Applied Drug Delivery Institute Appoints Jim Spavins to Advisory Board
Catalent Applied Drug Delivery Institute (CADDI) announced that Jim Spavins, a veteran pharmaceutical industry executive, has joined the institute’s advisory board.
On July 26, 2017, Catalent Applied Drug Delivery Institute (CADDI) announced that Jim Spavins, a veteran pharmaceutical industry executive, has joined the institute’s advisory board. Founded by Catalent, a global drug development, delivery, and supply partner, CADDI specializes in facilitating research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
“I look forward to working with the CADDI board to help rapidly advance innovative drug delivery solutions to patients,” said Spavins, in a company press release. “There has never been a more exciting time to leverage astonishing scientific advances in disease understanding with optimum delivery technology.”
With more than 36 years of industry and academic experience, Spavins has worked at all levels of research and development, reaching the position of senior vice-president of Pfizer’s Global Pharma Therapeutics Pharmaceutical Sciences group before starting his own consulting business, Spavins Consulting.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
